Published in Blood on February 26, 2009
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov (2009) 4.12
Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. J Pathol (2010) 2.58
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood (2009) 2.42
Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood (2010) 1.92
Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. Cancer Cell (2013) 1.86
Zebrafish screen identifies novel compound with selective toxicity against leukemia. Blood (2012) 1.81
The role of NOTCH1 signaling in T-ALL. Hematology Am Soc Hematol Educ Program (2009) 1.62
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev (2010) 1.54
Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis. Mol Cancer Ther (2010) 1.45
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A (2010) 1.27
Blockade of individual Notch ligands and receptors controls graft-versus-host disease. J Clin Invest (2013) 1.27
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood (2014) 1.23
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood (2009) 1.23
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
Notch signaling is a critical regulator of allogeneic CD4+ T-cell responses mediating graft-versus-host disease. Blood (2010) 1.21
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest (2014) 1.17
Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther (2012) 1.09
NOTCH1 activation clinically antagonizes the unfavorable effect of PTEN inactivation in BFM-treated children with precursor T-cell acute lymphoblastic leukemia. Haematologica (2013) 1.06
Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. Mol Ther (2011) 1.05
Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol (2009) 1.04
Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood (2011) 1.03
NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res (2012) 1.02
Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell (2011) 0.98
Generation of anti-Notch antibodies and their application in blocking Notch signalling in neural stem cells. Methods (2012) 0.97
Divergent effects of supraphysiologic Notch signals on leukemia stem cells and hematopoietic stem cells. Blood (2012) 0.95
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy. Ther Adv Hematol (2013) 0.94
Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemia. Blood (2009) 0.94
Lessons from next-generation sequencing analysis in hematological malignancies. Blood Cancer J (2013) 0.94
Growth factor independence 1 antagonizes a p53-induced DNA damage response pathway in lymphoblastic leukemia. Cancer Cell (2013) 0.91
Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. Clin Cancer Res (2013) 0.91
γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res (2012) 0.83
Transient responses to NOTCH and TLX1/HOX11 inhibition in T-cell acute lymphoblastic leukemia/lymphoma. PLoS One (2011) 0.83
Targeting Notch to overcome radiation resistance. Oncotarget (2016) 0.82
GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia. Leukemia (2011) 0.82
MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematol (2013) 0.80
The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. Blood Cancer J (2011) 0.80
Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. Blood Cancer J (2012) 0.80
Notch1 signaling is involved in regulating Foxp3 expression in T-ALL. Cancer Cell Int (2013) 0.80
Notch targeting 2.0. Blood (2009) 0.79
Gamma secretase inhibitors enhance vincristine-induced apoptosis in T-ALL in a NOTCH-independent manner. Apoptosis (2014) 0.78
The challenge of targeting notch in hematologic malignancies. Front Pediatr (2014) 0.78
Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment. Blood (2016) 0.76
Trib2 Suppresses Tumor Initiation in Notch-Driven T-ALL. PLoS One (2016) 0.76
Collaborating Pathways that Functionally Amplify NOTCH1 Signals in T-Cell Acute Lymphoblastic Leukemia. J Hematol Transfus (2013) 0.75
Notch ankyrin repeat domain variation influences leukemogenesis and Myc transactivation. PLoS One (2011) 0.75
High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia. Blood (2016) 0.75
NF-κB in T-cell Acute Lymphoblastic Leukemia: Oncogenic Functions in Leukemic and in Microenvironmental Cells. Cancers (Basel) (2010) 0.75
Oncogenic Notch signaling in T-cell and B-cell lymphoproliferative disorders. Curr Opin Hematol (2016) 0.75
Limiting Thymic Precursor Supply Increases the Risk of Lymphoid Malignancy in Murine X-Linked Severe Combined Immunodeficiency. Mol Ther Nucleic Acids (2016) 0.75
Synergistic antileukemic therapies in NOTCH1-induced T-ALL. Proc Natl Acad Sci U S A (2017) 0.75
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature (2005) 11.49
Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature (2006) 7.01
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev (2006) 6.19
Notch signals control the fate of immature progenitor cells in the intestine. Nature (2005) 6.13
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med (1996) 4.79
Notch signalling limits angiogenic cell behaviour in developing zebrafish arteries. Nature (2007) 4.65
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling. Mol Cell Biol (2003) 4.43
Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem (2004) 4.27
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci (2004) 3.85
Notch promotes survival of pre-T cells at the beta-selection checkpoint by regulating cellular metabolism. Nat Immunol (2005) 3.51
The rhombotin family of cysteine-rich LIM-domain oncogenes: distinct members are involved in T-cell translocations to human chromosomes 11p15 and 11p13. Proc Natl Acad Sci U S A (1991) 3.12
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
The multifaceted role of Notch in cancer. Curr Opin Genet Dev (2006) 3.07
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2006) 3.04
Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol Cell Biol (2006) 2.94
Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A (2006) 2.92
SCL and LMO1 alter thymocyte differentiation: inhibition of E2A-HEB function and pre-T alpha chain expression. Nat Immunol (2000) 2.87
Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol (2006) 2.85
TTG-2, a new gene encoding a cysteine-rich protein with the LIM motif, is overexpressed in acute T-cell leukaemia with the t(11;14)(p13;q11). Oncogene (1991) 2.71
An activated form of Notch influences the choice between CD4 and CD8 T cell lineages. Cell (1996) 2.42
Site-specific recombination of the tal-1 gene is a common occurrence in human T cell leukemia. EMBO J (1990) 2.38
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood (2007) 2.29
The t(11;14)(p15;q11) in a T-cell acute lymphoblastic leukemia cell line activates multiple transcripts, including Ttg-1, a gene encoding a potential zinc finger protein. Mol Cell Biol (1989) 2.24
Notch activation is an early and critical event during T-Cell leukemogenesis in Ikaros-deficient mice. Mol Cell Biol (2006) 2.09
Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling. Chem Biol (2007) 2.02
Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood (2007) 2.01
Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J (1996) 1.98
TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell (2004) 1.88
The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res (2007) 1.85
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood (2008) 1.84
Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood (2005) 1.84
Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats. Mol Cell Biol (2004) 1.78
Involvement of the putative hematopoietic transcription factor SCL in T-cell acute lymphoblastic leukemia. Blood (1992) 1.53
An scl gene product lacking the transactivation domain induces bony abnormalities and cooperates with LMO1 to generate T-cell malignancies in transgenic mice. EMBO J (1997) 1.43
Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5' part of the tal-1 gene. Oncogene (1991) 1.39
Does activation of the TAL1 gene occur in a majority of patients with T-cell acute lymphoblastic leukemia? A pediatric oncology group study. Blood (1995) 1.38
Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. Blood (2003) 1.38
Structural characterization of SIL, a gene frequently disrupted in T-cell acute lymphoblastic leukemia. Mol Cell Biol (1991) 1.34
A carboxy-terminal deletion mutant of Notch1 accelerates lymphoid oncogenesis in E2A-PBX1 transgenic mice. Blood (2000) 1.31
Notch1 promotes survival of E2A-deficient T cell lymphomas through pre-T cell receptor-dependent and -independent mechanisms. Blood (2006) 1.22
T-cell-directed TAL-1 expression induces T-cell malignancies in transgenic mice. Cancer Res (1996) 1.17
p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Oncogene (2006) 1.12
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther (2010) 5.24
ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading. Cancer Cell (2010) 3.25
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol (2006) 2.85
The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem (2004) 2.65
Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem (2005) 2.41
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog (2009) 2.31
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology (2009) 2.17
NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem (2007) 2.13
Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol (2007) 2.06
RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3. Nature (2013) 1.98
Kruppel-like factor 2 (KLF2) regulates proinflammatory activation of monocytes. Proc Natl Acad Sci U S A (2006) 1.95
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med (2009) 1.68
Deletion of the gene encoding G0/G 1 switch protein 2 (G0s2) alleviates high-fat-diet-induced weight gain and insulin resistance, and promotes browning of white adipose tissue in mice. Diabetologia (2014) 1.49
Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem (2005) 1.45
Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell (2012) 1.43
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res (2009) 1.41
Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell (2012) 1.40
Response of rat intracranial 9L gliosarcoma to microbeam radiation therapy. Neuro Oncol (2002) 1.36
A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol (2011) 1.36
Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol (2010) 1.30
Identification of prostate cancer modifier pathways using parental strain expression mapping. Proc Natl Acad Sci U S A (2007) 1.29
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood (2014) 1.23
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res (2010) 1.19
Conditional Niemann-Pick C mice demonstrate cell autonomous Purkinje cell neurodegeneration. Hum Mol Genet (2009) 1.18
Mechanism for KRIT1 release of ICAP1-mediated suppression of integrin activation. Mol Cell (2013) 1.17
The TAL1 complex targets the FBXW7 tumor suppressor by activating miR-223 in human T cell acute lymphoblastic leukemia. J Exp Med (2013) 1.14
Murine EMT-6 carcinoma: high therapeutic efficacy of microbeam radiation therapy. Radiat Res (2003) 1.10
Structural basis for small G protein effector interaction of Ras-related protein 1 (Rap1) and adaptor protein Krev interaction trapped 1 (KRIT1). J Biol Chem (2012) 1.09
The death domain kinase RIP1 is essential for tumor necrosis factor alpha signaling to p38 mitogen-activated protein kinase. Mol Cell Biol (2003) 1.05
Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Blood (2011) 1.03
NOTCH1 inhibition in vivo results in mammary tumor regression and reduced mammary tumorsphere-forming activity in vitro. Breast Cancer Res (2012) 1.02
The Notch1/c-Myc pathway in T cell leukemia. Cell Cycle (2007) 0.99
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res (2009) 0.97
A quantitative volumetric micro-computed tomography method to analyze lung tumors in genetically engineered mouse models. Neoplasia (2009) 0.94
Essential functions for ID proteins at multiple checkpoints in invariant NKT cell development. J Immunol (2013) 0.94
Structural basis for paxillin binding and focal adhesion targeting of β-parvin. J Biol Chem (2012) 0.92
NFKB1 is a direct target of the TAL1 oncoprotein in human T leukemia cells. Cancer Res (2006) 0.89
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell (2016) 0.87
Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg Med Chem Lett (2009) 0.84
Inhibition of rapamycin-induced AKT activation elicits differential antitumor response in head and neck cancers. Cancer Res (2013) 0.81
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Transl Oncol (2012) 0.81
Activation of NOD receptors by Neisseria gonorrhoeae modulates the innate immune response. Innate Immun (2013) 0.80
Apolipoprotein E genotype and neurological disease onset in Niemann-Pick disease, type C1. Am J Med Genet A (2012) 0.79
Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors. Bioorg Med Chem Lett (2012) 0.75
Correction: Repression of Ccr9 transcription in mouse T lymphocyte progenitors by the notch signaling pathway. J Immunol (2015) 0.75